Important Information for Intellia Therapeutics Securities Holders
On April 3, 2025, Rosen Law Firm released a press release reminding purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2025 lead plaintiff deadline.
What Does This Mean for Intellia Therapeutics Securities Holders?
If you purchased Intellia securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is pursuing the case on behalf of the investors seeking to recover their investment losses.
Why Was This Class Action Filed?
The complaint alleges that Intellia Therapeutics and certain of its top executives made false and misleading statements and failed to disclose material information about the company’s business, operations, and prospects. Specifically, the complaint alleges that the defendants failed to disclose that the company’s lead product candidate, a gene-editing therapy for sickle cell disease and beta-thalassemia, was experiencing manufacturing issues that would delay its commercial launch.
What’s Next for Intellia Therapeutics Securities Holders?
The lead plaintiff deadline is April 14, 2025. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
How Will This Affect You?
If you purchased Intellia securities during the Class Period and suffered investment losses, you may be able to recover your losses through the contingency fee arrangement. The Rosen Law Firm will represent you without any upfront costs or out-of-pocket expenses.
How Will This Affect the World?
The outcome of this class action could have significant implications for the gene-editing industry, as well as for investors in biotech companies. If the allegations are proven true, it could lead to increased scrutiny and regulation of the industry, as well as potentially significant damages for investors.
Conclusion
If you purchased Intellia Therapeutics securities between July 30, 2024 and January 8, 2025, and suffered investment losses, you may be entitled to compensation. The lead plaintiff deadline is April 14, 2025. Contact the Rosen Law Firm to discuss your options for recovering your losses.
- Rosen Law Firm reminds Intellia Therapeutics securities holders of the April 14, 2025 lead plaintiff deadline.
- If you purchased Intellia securities during the Class Period and suffered investment losses, you may be entitled to compensation.
- The complaint alleges that Intellia and certain executives made false and misleading statements about the company’s lead product candidate.
- The lead plaintiff deadline is April 14, 2025. Contact the Rosen Law Firm to discuss your options for recovering your losses.
